FDA, ap and personalized genetic medicines
Digest more
The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing ...
As regulatory authorities accelerate the use of New Approach Methodologies (NAMs), the drug discovery landscape is changing dramatically. This webinar explores how NAMs, immunology-driven ...
Explore the debate surrounding animal testing as new methods may jeopardise patient safety if not properly validated.
Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of cheaper, safer pharmaceuticals as well as alleviating animal suffering. But ...
Draper recently received an up to $26.7 million other transaction award (OTA) from the Advanced Research Projects Agency for Health (ARPA-H). The award supports the agency's Computational ADME-Tox and ...
DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human‑Relevant New Approach Methodologies (NAMs) ZURICH/SCHLIEREN, Switzerland, December 24, 2025 – ...
Although new approach methodologies (NAMs) are not that new, they remain a crucial and evolving aspect of the development and production of biopharmaceuticals. “NAMs have been around for 20 ...
IQVIA Holdings has signed an agreement to acquire selected discovery service assets from Charles River Laboratories, aiming to expand its end-to-end capabilities. The acquisition includes five sites ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results